AKT1 and metabolic disease: Among the family of serine/threonine protein kinases, GSK-3 has proven to be a central player in the core molecular signaling of different chronic diseases, including metabolic diseases, neurological diseases, and cancer [2], and therefore emerged as a potential drug target [29].